Skip to main content
. 2023 Jan 27;13:1008828. doi: 10.3389/fonc.2023.1008828

Figure 2.

Figure 2

(A) Timeline of patient preparation and CAR-T therapy for patient 1 from peripheral blood collection to 1 month after anti-BCMA CAR-T cell infusion, including bridging cryoablation, lymphodepleting chemotherapy, and CAR-T infusion. (B) Changes in body temperature after CAR-T cell infusion. (C) The levels of IL-6, TNF-α, C-reactive protein and D-dimer in serum at different time points after CAR-T cell infusion. (D, E) The percentage of anti-BCMA CAR-T cells in peripheral blood mononuclear cells (PBMCs) at different time points. The plot was gated on PBMCs. (F) CT-guided percutaneous cryoablation rapidly induced liquefaction necrosis of the neck mass. PET/CT showed that the neck mass was eliminated 1 month after combination therapy with cryoablation and CAR-T therapy, and it remained in remission 80 days after CAR-T cell infusion. (G) The neck mass showed a marked reduction in size 1 month after CAR-T cell infusion. (H) Flow cytometry analyses showed that MM cells was remarkably decreased in bone marrow 1 month after CAR-T cell infusion. The plot was gated on CD19 negative, CD45 dim or negative and/or CD56 positive cells.